Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MPO | P05164 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.57 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.57 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.57 |
| ▸ | FEN1 | P39748 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295502 | 0.88 | ALDH1A1 (0.89) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL7655992 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL30089550 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL14692183 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL17485188 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL4199990 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL8074180 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL30581253 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL1662185 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 | |
| SCHEMBL8692730 | 0.83 | CYP1A2 (0.76) | ALDH1A1HPGDKDM4EMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-106866625-B | Preparation method of ketanserin | 上海鼎雅药物化学科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6407116-B1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROQUINAZOLINE DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES, AND ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1026160-A1 | NITROGENOUS FUSED-RING COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME, AND DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| WO-1993021163-A1 | QUINAZOLONES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1993-10-28 | — | — | WO | disclosed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | ALDH1A1 887/4885HPGD 2224/4885KDM4E 1821/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | ALDH1A1 1738/4885HPGD 614/4885KDM4E 1069/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | ALDH1A1 1738/4885HPGD 614/4885KDM4E 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.